These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 3037302)
21. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Beck WT; Danks MK Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118 [TBL] [Abstract][Full Text] [Related]
22. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development. Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224 [TBL] [Abstract][Full Text] [Related]
23. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity. Barret JM; Calsou P; Larsen AK; Salles B Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322 [TBL] [Abstract][Full Text] [Related]
24. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343 [TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202 [TBL] [Abstract][Full Text] [Related]
26. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line. Sullivan DM; Eskildsen LA; Groom KR; Webb CD; Latham MD; Martin AW; Wellhausen SR; Kroeger PE; Rowe TC Mol Pharmacol; 1993 Feb; 43(2):207-16. PubMed ID: 8094226 [TBL] [Abstract][Full Text] [Related]
27. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine. Sorensen M; Sehested M; Jensen PB Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525 [TBL] [Abstract][Full Text] [Related]
28. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance. Baguley BC; Holdaway KM; Fray LM J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584 [TBL] [Abstract][Full Text] [Related]
29. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009 [TBL] [Abstract][Full Text] [Related]
30. Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Mattern MR; Mong SM; Bartus HF; Mirabelli CK; Crooke ST; Johnson RK Cancer Res; 1987 Apr; 47(7):1793-8. PubMed ID: 3028614 [TBL] [Abstract][Full Text] [Related]
31. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. Tan KB; Mattern MR; Eng WK; McCabe FL; Johnson RK J Natl Cancer Inst; 1989 Nov; 81(22):1732-5. PubMed ID: 2553992 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II as a target of antileukemic drugs. Zwelling LA; Estey E; Bakic M; Silberman L; Chan D NCI Monogr; 1987; (4):79-82. PubMed ID: 2819736 [TBL] [Abstract][Full Text] [Related]
33. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Holm C; Covey JM; Kerrigan D; Pommier Y Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254 [TBL] [Abstract][Full Text] [Related]
34. Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Lorico A; Rappa G; Srimatkandada S; Catapano CV; Fernandes DJ; Germino JF; Sartorelli AC Cancer Res; 1995 Oct; 55(19):4352-60. PubMed ID: 7671247 [TBL] [Abstract][Full Text] [Related]
35. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells. de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463 [TBL] [Abstract][Full Text] [Related]
36. Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells. Kamath N; Grabowski D; Ford J; Drake F; Kerrigan D; Pommier Y; Ganapathi R Cancer Commun; 1991 Feb; 3(2):37-44. PubMed ID: 1995027 [TBL] [Abstract][Full Text] [Related]
37. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Morgan SE; Cadena RS; Raimondi SC; Beck WT Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639 [TBL] [Abstract][Full Text] [Related]
38. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity. Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887 [TBL] [Abstract][Full Text] [Related]
39. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Nitiss JL; Liu YX; Hsiung Y Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128 [TBL] [Abstract][Full Text] [Related]
40. Characterization of a DNA topoisomerase IIalpha gene rearrangement in adriamycin-resistant P388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase IIalpha and the retinoic acid receptor alpha locus. McPherson JP; Brown GA; Goldenberg GJ Cancer Res; 1993 Dec; 53(24):5885-9. PubMed ID: 8261398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]